Search
Osimertinib: indicació avaluada; tractament de pacients adults amb càncer de pulmó no microcític avançat o metastàsic amb mutació EGFR T790M positiva
(2018-07-05)
Lung cancer is the leading cause of cancer-related mortality around the world. The most frequent histological subtype (85% of patients) is non-microcytic lung cancer (CPNM). CPNM is classified according to histology in ...
Dapagliflozina per al tractament de la insuficiència cardíaca crònica amb fracció d’ejecció reduïda
(2021-09-16)
Heart failure (HF) is a clinical syndrome characterized by a number of symptoms (difficulty breathing, malleolar edema, and fatigue) that may be accompanied by signs (increased jugular venous pressure, pulmonary crackling, ...
Tisagenlecleucel per al tractament de la leucèmia limfoblàstica aguda
(2019-03-21)
Tisagenclecleucel is a gene therapy that contains manipulated T-lymphocytes of the same patient previously, in order to express, in their membrane, a chimeric antigenic receptor or CAR. This receptor allows the recognition ...
Lumacaftor/ivacaftor (Orkambi®) per al tractament de la fibrosi quística
(2019-10-15)
Cystic fibrosis (CF) is an autosomal recessive disorder caused by mutations in the gene that encodes the transmembrane conductance regulator of CF (CFTR), a protein that acts as a chloride channel. Viscous secretions ...
Tractament del carcinoma de cèl·lules renals avançat en segona línia: informe d’avaluació de resultats
(2021)
The data reported by prescribers have been selected for patients who have been treated in the Integral Health System of Catalonia (SISCAT) with axitinib, cabozantinib (anti-VEGF), nivolumab (anti-PDL1) or everolimus (mTOR ...